We have previously demonstrated that vascular endothelial growth factor (VEGF) is critical for cerebral angiogenesis in middle-aged female rats and may play a role in the flow-preserving neuroprotective actions of estrogen through its angiogenic and antiapoptotic properties. Here, we attempt to elucidate the effects of estrogen and the specific estrogen receptor (ER) subtype in cerebral VEGF/Akt/NO pathways and cerebral angiogenesis using 15-week old female mice that are either wild-type (WT), lack estrogen receptor α (ERαKO) or β (ERβKO). Protein levels of VEGF and basic signaling molecules of VEGF angiogenic pathway in the frontal cortex were expressed as follows, as revealed by ELISA and immunoblotting : a) VEGF; WT: ERαKO: ERβKO, 47 ± 15: 27 ± 5: 28 ± 5 pg/mg, respectively (P < 0.01); b) KDR decreased about 40% in both ERαKO and ERβKO compared to WT; c) Akt was significantly down regulated in both ERαKO and ERβKO compared to WT; d) phosphorylated Akt (pAkt); WT: ERαKO: ERβKO, 0.6 ± 0.2: 0.3 ± 0.01: 0.3 ± 0.1 units/mg, respectively; e) phosphorylated eNOS significantly decreased about 45% in both ERαKO and ERβKO compared to WT. Cerebral capillary density decreased in both ERαKO and ERβKO compared to WT. Thus, it can be concluded that in female mice VEGF/Akt/ eNOS pathway plays an important role in cerebral angiogenesis and that both ER subtypes are involved in the regulation of VEGF and its signaling molecule expression in the frontal cortex.
Although the protective effects of estrogen on the vascular system have been extensively studied, knowledge of estrogen's effects on cerebral vessels and, specifically, its impact on neuroprotection is lacking and unclear. This is particularly true in human subjects where there are various confounding variables, such as experimental design, age and socioeconomic status. In contrast, data from animal studies are more cohesive and there is a consensus on the neuroprotective effects of estrogen perhaps because variables are easier to control and a more extensive molecular data exists. To date, there are two best known and distinctive estrogen receptors (ERs) that mediate biological effects of estrogen in mammals: the well documented estrogen receptor alpha and the recently discovered estrogen receptor beta (22, 25) . The expression of these two receptors in different tissue types varies among species (9, 24, 44) . While recent studies (New York, NY, USA). The mice were used at 15 weeks of age (n = 12 for each group). The ERαKO mouse was developed by Kenneth S. Korach of the National Institute of Environmental Health Sciences (NIEHS) and colleagues in 1993 by targeting the Esr1 gene in E12TG2a ES cells and injecting the targeted cells into C57BL/6J blastocysts (30) . Resultant chimeras were backcrossed to C57BL/6 for ten generations (N10). Taconic received stock from the NIEHS in 1998, and animals were transferred to Taconic for commercial production in 2000. Homozygotes and heterozygotes were generated by mating male and female heterozygous ERαKO mice. ERαKO mice used in the present study completely lack functional estrogen receptor alpha protein, had survived into adulthood, but are infertile, indicating the necessity of estrogen for proper gonadal development in both sexes (data sheet, Taconic). The ERβKO mouse was developed by Oliver Smithies and John Kreg of the University of North Carolina, Kenneth Korach of NIEHS and Jan-Ake Gustafsson of the Karolinska Institute (23) . The model was created by targeting the Esr2 gene in ES cells of the BK4 subline of E14TG2a (129P2/ OlaHsd) and injecting the targeted ES cells into C57BL/6 blastocysts. Resultant chimeras were backcrossed to C57BL/6 for eight generations (N8). Homozygotes were generated by intercrossing heterozygote ERβKO mice. Stock was received from NIEHS in January 2001 and the animals were transferred to Taconic for commercial production in September 2001. The mice were derived by embryo transfer through backcrossing to C57BL/6NTac (N9). The colony is maintained by mating of homozygous males to heterozygous females. According to data sheet from Taconic, male and female homozygotes of ERβKO completely lack functional estrogen receptor beta proteins, develop normally and survive into adulthood. The frontocortical tissues of brain were harvested under an overdose of sodium pentobarbital (80 mg/ kg), and immediately frozen in liquid nitrogen and stored at −80°C. Some tissues were analyzed using either enzyme-linked immunosorbent assay (ELISA), immunoblotting, and the others were fixed overnight in 4% paraformaldehyde and routinely embedded in paraffin wax for analyses of capillary morphology or immunohistochemistry. For ELISA and immunoblotting, the harvestted brain [frontocortical tissues] was minced and homogenized in PBS on ice, then centrifuged at 10,000 × g for 15 min at 4°C, and the resulting supernatants were stored at −80°C. Appropriate amount of PBS was added to the fronhave noted the positive and, in some aspects, negative effects of estrogen in the brain, the specific involvement and function of the two receptors and their impact on various cellular pathways remain ambiguous and thus need further study (6, 7, 10, 46) . The two noted mammalian ERs are variably expressed in the brain. ERα has been shown to reside in the hippocampus, hypothalamic/preoptic continuum, amygdala, midbrain, dorsal horn of the spinal cord and the dorsal root ganglia, while ERβ is known to be expressed in these areas, as well as in other regions, such as the cerebellum (7, 45). Furthermore, the role of each ER in neuroprotection is dependent on the cellular parameters analyzed, the type of injury, as well as the location of injury (7). Estrogen replacement therapy may also act in the nervous system via less known pathways, such as via ion channels of neurotransmitters and through non-receptor-mediated mechanisms (7, 13, 28, 52). The interconnectedness of these pathways as well as ER's functions are inextricably linked and their further study could shed more insights on the role of estrogen in the brain. Vascular endothelial growth factor (VEGF) plays significant and critical regulatory roles in cerebral angiogenesis and, potentially, could be an important mediator of estrogen's neuroprotective effects via its angiogenic and antiapoptotic properties. Although various animal studies have shown estrogen's intrinsic effects on the cerebral vasculature and its associated neuroprotection and neurogeneration, the specific function of ERs and the underlying mechanisms remain unclear (42, 43) . In the present study we attempt to elucidate the effects of estrogen and the specific ER subtype mediating these effects in cerebral VEGF/Akt/NO pathways and cerebral angiogenesis using 15-week old female mice that are either wild-type (WT), lack estrogen receptor α (ERαKO) or β (ERβKO).
MATERIALS AND METHODS
Animals. This study was conducted in accordance with the National Institutes of Health (NIH) guidelines on the use of laboratory animals and with approval of the Hokkaido University Graduate School of Medicine Animal Care and Use Committee. Estrogen receptor alpha knockout (ERαKO) (001480-M-F c5BL/6-EstrA(tm) N10 Female, homozygous), estrogen receptor beta knockout (ERβKO) (001954-M-F B6.129-Esr2<tm1> Female, homogzygous), and age-matched wild type (WT) female mice (B6-F c57BL/6NTac Female) were purchased from Taconic cence.
Immunofluorescence staining. For immunohistochemical studies, tissue specimens were fixed in 10% buffered formalin solution, dehydrated and then embedded in paraffin. The tissues were sliced in 4 μm sections transversely, deparaffinized and treated for 10 min with citrate buffer (10 mM citric acid, pH 6.0) in a microwave oven (750 W) before immunostaining. In another set of experiments, frozen tissue samples were cut by cryostat in 8 μm-thick sections, fixed in acetone and air-dried. To prevent non-specific staining by secondary antibody, the sections were blocked by non-immune serum (1% bovine albumin in Tris buffer) for 30 min at room temperature. After overnight incubation at 4°C with primary antibodies, the sections were rinsed in phosphate buffered saline and then exposed to the fluorescence secondary antibody, Cy3-conjugated anti-mouse IgG or fluorescein-conjugated AffiniPure rabbit anti-goat IgG (Jackson ImmunoResearch Laboratories, Westgrove, PA, USA) for 2 h, according to the manufacturer's instructions. The samples that were processed without primary antibodies served as negative controls. Immunofluorescence images were observed under a Laser Scanning Confocal Imaging System (MRC-1024; Bio-Rad Laboratories, Hemel Hempstead, Herts, UK).
Capillary morphology. Histochemical staining with the lectin Griffonia simplicifolia (GSA-B4) is a sensitive and reliable method to visualize the capillary vasculature. Eight-micrometer-thick serial frozen coronal sections of frontal cortex were stained with GSA-B4 (Sigma Chemical, St. Louis, MO). The sections were fixed with acetone, air dried, and placed in PBS. After being treated with 3% H 2 O 2 in methanol and washed in PBS, the sections were incubated with GSA-B4 (biotin-labeled) (1 : 100 dilution in PBS) overnight at 4°C, followed by reaction with streptoavidin conjugated to peroxidase (Nichirei Corp., Tokyo, Japan) and through rinse in PBS. For visualization diaminobenzidine/H 2 O 2 as chromogen was used. To enhance the diaminobenzidine reaction, the sections were rinsed with 0.05 M NaHCO 3 (pH 9.6) and then incubated in a diaminobenzidine enhancing solution (Vector Laboratories, Burlingame, CA). Counting of stained capillaries was made in cross-sections in 30 fields per sample (section on slide) at a final magnification of × 400 by an imageanalyzing software (microcomputer imaging device, Imaging Research, St. Catharine, Ontario, Canada). Furthermore, the number of lectin-stained capillaries tocortical tissues before homogenization, based on weight. Total protein concentration of supernatant was then determined using the bicinchoninic acid protein assay (Pierce, Rockford, IL) and data generated from the present experiments were normalized for each sample, based on the total protein concentration.
ELISA. Levels of VEGF, KDR (VEGF type 2 receptor), caspase-3 (R&D Systems, Minneapolis, MN, USA), and phospho-Akt (Thr 308 and Ser 473) (BioSource International, Inc., Camarillo, California, USA) in the supernatant of frontocortical extracts were determined using the quantitative sandwich enzyme immunoassay technique, according to the manufacturer's instructions. The values obtained from ELISA were normalized by total protein concentration for each sample and then used for statistical analysis.
Western blot analysis. The following commercially available antibodies were used for Western blot analysis: a) anti-human VEGF rabbit polyclonal antibody (Immuno-Biological Laboratories, Fujioka, Japan), b) anti-human Flt-1 rabbit polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), c) anti-human KDR rabbit polyclonal antibody (Santa Cruz Biotechnology), d) anti-mouse Ser473-phospho-Akt rabbit polyclonal antibody (Cell Signaling, Beverly, MA, USA), e) anti-human endothelial nitric oxide synthase (eNOS) rabbit polyclonal antibody (Affinity BioReagents, Golden, CO, USA), f) anti-bovine basic fibroblast growth factor (bFGF) mouse monoclonal antibody (Upstate Biotechnology, Lake Placid, NY, USA), g) anti-human Bcl-2 rabbit polyclonal antibody (Santa Cruz Biotechnology), h) anti-Akt rabbit polyclonal antibody (Cell Signaling), i) anti-mouse estrogen receptor alpha rat monoclonal antibody (Novocastra Laboratories, Benton Lane, Newcastle upon Tyne, UK), j) anti-human estrogen receptor beta rabbit polyclonal antibody (Affinity BioReagents), and k) anti-Xenopus laevis beta-actin mouse monoclonal antibody (Abcam, Cambridge, MA, USA). The protein concentrations of supernatants were determined using the bicinchoninic acid protein assay (Pierce). Immunoblotting was performed as described in our previous report (16) . Samples of frontocortical tissue homogenates were run on a 7.5 -10% SDS-polyacrylamide gel and electrotransferred to a polyvinylidene diflouride filter membrane. The membrane was then blotted with the indicated antibody and processed via chemilumines-
RESULTS

General features of experimental animals
At 16 weeks of age, the body weights of ERαKO (23.8 ± 1.5 g) and ERβKO mice (25.6 ± 1.6 g) were significantly (P < 0.01) greater than that of WT mice (20.5 ± 1.1 g). The plasma estrogen level was higher in ERαKO (1.9 ± 0.6 pg/mL) than in WT (0.9 ± 0.1 pg/mL) and ERβKO mice (0.8 ± 0.3 pg/mL). (Fig. 1A, B) .
Concentrations of VEGF in serum and frontocortical tissues
was quantified by two independent researchers in a double-blinded study. Care was taken to avoid counting the same single capillary twice. Any microvessel (defined as a vessel having internal diameter < 10 μm) that had no apparent lumen was considered as a single capillary. Capillary density was also assessed microscopically on 5-μm-thick deparaffinized tissue sections that were immunostained by anti-von Willebrand factor (vWF) antibody (Dako, Hamburg, Germany) or CD34 (Santa Cruz Biotechnology). The antibodies were made visible by a secondary exposure of the sections to Cy3-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories).
Statistical analysis. Results were expressed as mean ± S.E. Data were compared using one-way ANOVA. Post hoc comparisons were made with Fisher's protected least significance t-test for multiple comparisons. Differences were considered significant at P < 0.05. 
Expression of VEGF receptors KDR and Flt-1 in frontocortical tissues
Levels of KDR, an angiogenic receptor of VEGF, were comparable to those of VEGF in the frontocortical tissues of both ERαKO and ERβKO mice. Thus, frontocortical levels of KDR protein in ERαKO and ERβKO mice decreased by 40% compared to WT mice, as demonstrated in Fig. 1C . Frontocortical levels of Flt-1 protein, a vascular permeability receptor of VEGF, also decreased by around 35% in ERαKO and ERβKO, in comparison with WT mice, when analyzed by immunoblotting (Fig. 1D) .
Akt phosphorylation and eNOS expression
The serine/threonine kinase Akt is an important downstream molecule of VEGF angiogenic signaling (32, 34) . Frontocortical expression of Akt, dually phosphorylated at Thr308 and Ser473, was significantly reduced in ERαKO and ERβKO mice compared to WT mice ( Fig. 2A, B) . No apparent difference in total Akt level among groups was noted. Activation of Akt phosphorylation activates eNOS, which in turn induces NO production (32, 34) . Frontocortical expression of eNOS (phosphorylated) was significantly less in ERαKO and ERβKO mice than in WT mice (Fig. 2C) .
Immunofluorescence detection of VEGF and its signaling molecules
Immunofluorescence data revealed down-regulation of VEGF, KDR, and eNOS in frontocortical tissues in both ERαKO and ERβKO mice compared to WT mice (Fig. 3) , consistent with immunoblotting and ELISA data. Endothelium and smooth muscle cells in blood vessels (arteries, veins, capillaries) showed the immunoreactivities for VEGF, KDR, and eNOS. Positive immunoreactivities for VEGF and KDR were also observed in nuclei of neurons and glial cells.
Apoptosis-related markers
To assess whether deletion of estrogen receptors causes or is associated with apoptotic cell death and delineate the estrogenic pathway mediating this effect in the brain, we investigated several apoptotic markers. Frontocortical expression levels of two important pro-apoptotic molecules, caspase-3 and Bax, were unaffected by deletion of estrogen receptors (Fig. 4A, 4B) . In contrast, expression of Bcl-2, which suppresses activation of caspase-3 protein through regression of cytochrome c release from mitochondria (3, 31), was significantly decreased in frontocortical tissues from ERαKO and ERβKO compared with WT mice (Fig. 4C) .
Expression of FGF-2
Finally, we investigated whether frontocortical expression of FGF-2, another important angiogenic growth factor, is altered by deletion of estrogen receptors. No significant change in the study groups was found (Fig. 4D) . cial effects of estrogen on the vasculature (30, 34, 38, 55) . For instance, several studies have shown that estrogen inhibits vascular remodeling in response to mechanical injury (1, 2, 35, 38) and hyperlipidemia (34) . Less is known and conflicting data exists, however, on the impact of estrogen on cerebral vessels, its role in neuroprotection and the underlying mechanisms (5, 17, 26, 41, 47, 54) . The lack of consensus is especially true in human compared to animal data. The main evidence pointing to a role for estrogen in cerebral vasculature are based on the facts that: 1) cerebral vessels express estrogen receptors in both smooth muscle and endothelial cell layers; 2) the incidence of cerebrovascular disorders, such as stroke, is higher in men than in women in all countries. The stroke is rare during female reproductive years, when levels of estrogen are high, but increases during postmenopausal period, when estrogen levels drop sharply (4, 36, 48); 3) estrogen provides protection against ischemic injury by preserving endothelial mitochondrial protection via ERα (12, 37) ; and 4) ovariectomy in animal models induces significant reduction in both total
Forebrain capillary morphology
Capillary density in the frontal cortex of ERKO mice, as determined by GS4 lectin staining and vWF immunostaining, was significantly lower compared with WT mice (Fig. 5) . Analysis of cerebral capillary density data showed similar decrease in capillary density in both ERαKO and ERβKO mice compared to WT mice.
DISCUSSION
Estrogen's vascular effects have been extensively studied, particularly in the reproductive organs. However, evidence from cerebral vessels is less clear, particularly in human subjects, where many variables exist, including experimental design, age, socioeconomic status and others. In the present study, we attempted to tease out the potential mechanisms underlying estrogen's cerebral vascular effects using ERKO mice. We show that estrogen's vascular effects are mediated by both receptor subtypes α and β, via VEGF/eNOS/Akt signaling mechanism.
There are numerous studies that show the benefi- therapy (15) . Although epidemiological reports have consistently supported the beneficial cerebrovascular effects of estrogen, data from very recent randomized studies contradict the findings of these earlier reports (5, 17, 26, 41, 47, 54, 57). These randomized studies have been criticized for their limited relevance to the traditional use of hormone replacement therapy (5, 14 17, 41) . Use of knockout mice, as utilized in the present study, makes it feasible to tease out the basic mechanisms underlying estrogen's cerebrovascular effects. The attenuation of VEGF expression and its signaling molecules in the cerebrovasculature of ERKO mice, as revealed here, suggests a role for estrogen in this tissue in females and that this effect is, in part, mediated by both estrogen receptor α and β. Data from several earlier studies in the brain and non-neuronal tissues are consistent with the current observations (19, 27, 33) . Specifically, exogenous cerebral capillary density and levels of VEGF and its receptor (KDR) in middle-aged female rats and the effects are reversed by estrogen replacement eNOS, and Akt), as well as those of Bcl-2 in the cerebrum. We conclude that estrogen has a neuroprotective effect through the regulation of the VEGFmediated cerebrovasculature and that this effect is mediated via both estrogen receptors. REFERENCES estrogen in ovariectomized rats induces VEGF expression in the brain (15) , and Mueller and others have shown that VEGF is likely activated by estrogen through a variant ERE (estrogen responsive element) localized 1.5 kb upstream from the VEGF transcription start site (33) . Furthermore, mutations of ERE by site-directed mutagenesis completely attenuate estrogen-induced expression of VEGF mRNA. Although levels of VEGF sharply dropped in ERKO mice, they were not completely attenuated, implying existence of either a compensatory mechanism, redundancy or other regulatory factors, such as endothelin-1, calcium ions, phorbol esters, cytokines, heavy metals, hypoxia, and other sex steroid hormones (11, 33, 49, 50) . Stimulation of VEGF with these factors may account for the "residual" levels of VEGF in the brain following estrogen receptor deletion. Even though data on the neuroprotective effects of estrogen are still controversial, there is ample evidence that supports this preposition, notably the gender difference in stroke survival provides a plausible explanation for the beneficial effects of estrogen (56, 58) . However, the mechanisms that underlie estrogen's neuroprotection and the role of the vasculature in this process are unclear. Factors believed to have protective effects on neuronal tissues, include sex steroids, neurotrophins, methylation of phospholipids, neurotransmitters, proteins, and nucleic acids (18, 51) . Here, we hypothesized and demonstrated that estrogen, acting via VEGF, provides neuroprotection by promoting expression of antiapoptotic factors, such as Bcl-2. We also show that deletion of both estrogen receptor subtypes mediates this process, possibly by promoting survival of vascular endothelial cells. Indeed, a large body of evidence suggests that VEGF/Akt signaling is crucial in endothelial cell survival (22, 59) . In addition, VEGF has been shown to induce Bcl-2 expression (29) , leading us to speculate that the diminished signaling of VEGF/Akt cascade in the brain of ERKO mice may contribute to the diminished levels of cerebral Bcl-2, which could in turn account for the predisposition of the female brain to the onset of cerebrovascular disorders, such as stroke. Other recent studies have proposed estrogen's role in the viability of mitochondria. Future studies should assess the abilities of these KO mice to endure stroke compared to estrogen-treated WT mice.
In conclusion, the present study reveals that the absence or deficiency of functional estrogen receptor in female mice disrupts levels of VEGF and components of its signaling machinery (KDR, Flt-1, 
